Company profile
Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Bezuclastinib | phase3 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04996875 | phase2 | recruiting | 2021-11-09 | 2025-09-19 | Cogent Biosciences, Inc. | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis |
| NCT05208047 | phase3 | recruiting | 2022-04-14 | 2025-09-30 | Cogent Biosciences, Inc. | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
| NCT05186753 | phase2 | active_not_recruiting | 2022-06-27 | 2025-05-22 | Cogent Biosciences, Inc. | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis |
| NCT07383506 | phase1 | recruiting | 2026-07-23 | 2029-07-01 | Cogent Biosciences, Inc. | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors |
| NCT07361562 | phase1 | recruiting | 2025-12-30 | 2028-05-01 | Cogent Biosciences, Inc. | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors |
FDA applications (0)
No records yet.